KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Total Non-Current Liabilities (2018 - 2025)

Historic Total Non-Current Liabilities for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $94.2 million.

  • Castle Biosciences' Total Non-Current Liabilities changed N/A to $94.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.2 million, marking a year-over-year change of. This contributed to the annual value of $75.4 million for FY2024, which is 2152.27% up from last year.
  • As of Q3 2025, Castle Biosciences' Total Non-Current Liabilities stood at $94.2 million.
  • Castle Biosciences' Total Non-Current Liabilities' 5-year high stood at $94.2 million during Q3 2025, with a 5-year trough of $32.5 million in Q4 2021.
  • Over the past 5 years, Castle Biosciences' median Total Non-Current Liabilities value was $48.1 million (recorded in 2022), while the average stood at $55.5 million.
  • In the last 5 years, Castle Biosciences' Total Non-Current Liabilities surged by 4776.16% in 2022 and then plummeted by 1128.35% in 2023.
  • Castle Biosciences' Total Non-Current Liabilities (Quarter) stood at $32.5 million in 2021, then skyrocketed by 47.76% to $48.1 million in 2022, then rose by 29.02% to $62.0 million in 2023, then grew by 21.52% to $75.4 million in 2024, then increased by 24.99% to $94.2 million in 2025.
  • Its last three reported values are $94.2 million in Q3 2025, $87.9 million for Q2 2025, and $75.4 million during Q4 2024.